Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

@article{Home2009RosiglitazoneEF,
  title={Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial},
  author={Philip D. Home and Stuart J Pocock and Henning Beck-Nielsen and Paula Curtis and Ramon Gomis and Markolf Hanefeld and Nigel P. Jones and Michel Komajda and John J. V. McMurray},
  journal={The Lancet},
  year={2009},
  volume={373},
  pages={2125-2135}
}
BACKGROUND Rosiglitazone is an insulin sensitiser used in combination with metformin, a sulfonylurea, or both, for lowering blood glucose in people with type 2 diabetes. We assessed cardiovascular outcomes after addition of rosiglitazone to either metformin or sulfonylurea compared with the combination of the two over 5-7 years of follow-up. We also assessed comparative safety. METHODS In a multicentre, open-label trial, 4447 patients with type 2 diabetes on metformin or sulfonylurea… 
Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.
TLDR
In this long-term, pragmatic trial, incidence of cardiovascular events was similar with sulfonylureas and pioglitazone as add-on treatments to metformin, although piog litazone was associated with fewer hypoglycaemia events.
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial
TLDR
Findings confirm the increased risk of HF events in people treated with rosiglitazone and support the recommendation that this agent should not continue to be used in people developing symptomatic HF while using the medication.
Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials
TLDR
Combination therapy of metformin and sodium-glucose cotransporter-2 inhibitors is a safe and efficacious alternative for patients with type 2 diabetes who are at risk of cardiovascular comorbidity.
Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study
TLDR
In patients with T2D failing prior hypoglycemic therapies, Pio combinations with SU or Met (especially Pio + Met) improved blood lipid and glycemic profiles, decreasing the proportion of patients with a high microvascular or macrovascular risk.
Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials
TLDR
The malignancies rates in these two randomised controlled clinical trials do not support a view that metformin offers any particular protection against malignancy compared with rosiglitazone, but they do not refute the possibility of a difference compared with sulfonylureas.
Efficacy and Safety of Pioglitazone Monotherapy in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
TLDR
Meta-analysis supported pioglitazone as an effective treatment option for T2DM patients to ameliorate hyperglycaemia, adverse lipid metabolism and blood pressure.
Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US
TLDR
Compared to rosiglitazone 4 mg plus glimepiride, liraglutide is a cost-effective treatment option for improving glucose control in T2DM, particularly at the 1.2-mg dose.
Cardiovascular safety and efficacy of combination therapy with metformin and sodium-glucose cotransporter-2 inhibitors versus metformin and sulfonylureas in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
TLDR
A combination therapy of metformin and sodium-glucose cotransporter-2 inhibitors is a safe and efficacious alternative to combination Therapy of met formin and sulphonylureas for patients with type 2 diabetes who are at risk of cardiovascular comorbidity.
Treatment of type 2 diabetes: New clinical studies and effects of GLP-1 on macrovascular complications.
TLDR
The results of this trial showed that early revascularization is not clearly beneficial, except in a subgroup of patients in whom surgical revascularized is indicated, and the use of GLP-1 analogs in the acute phase of myocardial ischemia in animal models provided promising results.
Database Evaluation of the Effects of Long‐Term Rosiglitazone Treatment on Cardiovascular Outcomes in Patients With Type 2 Diabetes
TLDR
In this community‐based cohort, 30 months of therapy with rosiglitazone treatment was associated with increased risk of CHF but was not associated withincreased risk of AMI, ACS, coronary revascularization, or all‐cause mortality.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 23 REFERENCES
Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study)
TLDR
Changes in BP were not accompanied by compensatory increases in heart rate, did not correlate with basal insulin sensitivity estimates and were not explained by changes in antihypertensive therapy between the various strata.
Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol
TLDR
The RECORD study should provide robust data on the extent to which rosiglitazone, in combination with metformin or sulphonylurea therapy, affects CV outcomes and progression of diabetes in the long term.
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
TLDR
The interim findings from this ongoing study were inconclusive regarding the effect of rosiglitazone on the overall risk of hospitalization or death from cardiovascular causes.
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
TLDR
The potential risks and benefits, the profile of adverse events, and the costs of these three drugs should all be considered to help inform the choice of pharmacotherapy for patients with type 2 diabetes.
A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure.
TLDR
After 52 weeks of treatment, RSG improved glycemic control but did not adversely affect LVEF in patients with T2DM and NYHA functional class I to II CHF.
Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus.
TLDR
To conclude, rosiglitazone and atorvastatin in combination achieved 2 goals: the reduction of LDL cholesterol to <100 mg/dl and the removal of small dense LDL in patients with type 2 diabetes mellitus.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
TLDR
The effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial were compared.
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
TLDR
Overall safety and tolerability was good with no change in the safety profile of pioglitazone identified; mortality rates from heart failure did not differ between groups.
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
TLDR
Since intensive glucose control with metformin appears to decrease the risk of diabetes-related endpoints in overweight diabetic patients, and is associated with less weight gain and fewer hypoglycaemic attacks than are insulin and sulphonylureas, it may be the first-line pharmacological therapy of choice in these patients.
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
TLDR
Patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes mellitus as well as the availability of outcome data for myocardial infarction and death from cardiovascular causes.
...
1
2
3
...